A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Aug 20, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with advanced stomach cancer that has spread to the liver. The study will look at how effective and safe a combination of three treatments—Sintilimab (an immune system booster), Ramucirumab (which helps block blood vessel growth to tumors), and chemotherapy—can be when given together as the first line of treatment. The goal is to see if this combination can improve the health outcomes for these patients, as well as to track any side effects that may occur.

To participate in this trial, patients must be between 65 and 74 years old and have a specific type of stomach cancer that is not suitable for surgery. They also need to have measurable cancer in the liver and must not have received prior systemic treatments. Participants will receive the combination treatment every three weeks for up to six cycles, followed by additional maintenance therapy until the disease progresses. Throughout the trial, patients will have regular imaging tests to monitor their condition. This study is not yet recruiting participants, but it aims to offer a new potential option for those facing advanced gastric cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntary participation in the clinical study; full understanding and informed consent to this study by signing the Informed Consent Form (ICF); willingness to follow and ability to complete all trial procedures.
• • 2. Patients with histologically or cytologically confirmed, unresectable, or who refuse surgical resection of locally advanced, recurrent, or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma (including signet-ring cell carcinoma, mucinous adenocarcinoma, hepatoid adenocarcinoma, etc.). (Note: For patients who relapse after neoadjuvant/adjuvant therapy, the time from the end of neoadjuvant/adjuvant therapy to disease relapse must be more than 6 months.)
• • 3. Patients, except those with recurrent disease after neoadjuvant/adjuvant therapy, must not have previously received systemic treatment.
• • 4. Participants must be histologically confirmed as having HER2-negative gastric cancer, GEJ cancer, or esophageal adenocarcinoma.
• • 5. There must be at least one measurable lesion in the liver assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) that can undergo repeat radiological evaluation; the radiological tumor assessment should be performed within 28 days prior to randomization.
• • 6. The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2 within 7 days prior to the first dose of medication.
• • 7. Availability of representative tumor tissue specimens, blood samples, and fecal samples for exploratory research.
• 8. Main organ functions must be normal, meeting the following criteria:
• • Liver Function Alanine Aminotransferase (ALT) ≤5.0 × ULN Aspartate Aminotransferase (AST) ≤5.0 × ULN
• Exclusion Criteria:
• • 1. History of other active malignancies within the past 5 years or currently having other active malignancies. Treated localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, and breast carcinoma in situ, are eligible for inclusion.
• • 2. Underwent surgery within 4 weeks prior to the start of the study treatment.
• • 3. Known history of severe allergy to any monoclonal antibodies or excipients.
• • 4. Previous use of PD-1 inhibitors, LAG-3 inhibitors, CTLA-4 inhibitors, or any other antibodies or drug treatments targeting T-cell co-stimulation or immune checkpoint pathways, including previous receipt of anti-tumor vaccines or other immunostimulatory anti-tumor therapies.
• • 5. Previous exposure to VEGF (vascular endothelial growth factor) or VEGFR inhibitors or any anti-angiogenesis medications.